Author

K. Laktionov

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Pemigatinib in the real-world management of advanced intrahepatic FGFR2-positive cholangiocarcinoma

Introduction. Cholangiocarcinoma (CC) is one of the most aggressive malignant tumors of the hepatobiliary tract with a poor prognosis, especially at the late stages. The targeted therapy with pemigatinib, a selective FGFR2 inhibitor, can be administered in a proportion (10–15%) of patients with intrahepatic cholangi...

M. Khagazheeva, A. R. Zaretsky, A. N. Koshmanova et al. · Meditsinskiy sovet = Medical... · 0 citations

Open access Sep 2026

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175].

INTRODUCTION In ADAURA, adjuvant osimertinib improved DFS and OS versus placebo in resected EGFR-mutated stage IB-IIIA NSCLC. We report a post hoc exploratory analysis of long-term OS post-adjuvant treatment completion. METHODS Patients (N = 682) were randomized to osimertinib or placebo until recurrence, treatment c...

Yi-Long Wu, M. Majem, T. John et al. · Journal of Thoracic Oncology · 1 citation

Open access Aug 2026

Resolution on the results of the expert council on the topic “Diagnosis and treatment of advanced non-small cell lung cancer with BRAF mutation: from the search for molecular targets to therapeutic strategies in real-world clinical practice”

On January 27, 2026, an Advisory Board was held to discuss issues of molecular genetic diagnosis of the BRAF V600E mutation in patients with advanced non-small cell lung cancer (NSCLC), as well as current treatment options for NSCLC patients with the BRAF V600E mutation. Next generation sequencing (NGS) is the most sen...

K. Laktionov, V. Breder, I. A. Demidova et al. · Malignant tumours · 0 citations